Aptorum Group Limited

2.64+0.0900+3.53%Vol 119.38K1Y Perf -20.18%
Apr 16th, 2021 16:00 DELAYED
BID2.55 ASK2.69
Open2.53 Previous Close2.55
Pre-Market- After-Market-
 - -  - -%
Target Price
22.00 
Analyst Rating
— — 0.00
Potential %
733.33 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★+     45.42
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap89.79M 
Earnings Rating
Neutral
Price Range Ratio 52W %
11.32 
Earnings Date
5th May 2021

Today's Price Range

2.402.64

52W Range

1.1614.23

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-8.01%
1 Month
-20.72%
3 Months
-20.24%
6 Months
-4.35%
1 Year
-20.18%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
APM2.640.09003.53
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date5th May 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume119.38K
Shares Outstanding34.01M
Trades Count580
Dollar Volume1.81M
Avg. Volume618.41K
Avg. Weekly Volume163.00K
Avg. Monthly Volume225.10K
Avg. Quarterly Volume679.30K

Aptorum Group Limited (NASDAQ: APM) stock closed at 2.64 per share at the end of the most recent trading day (a 3.53% change compared to the prior day closing price) with a volume of 120.26K shares and market capitalization of 89.79M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 39 people. Aptorum Group Limited CEO is Ian Huen.

The one-year performance of Aptorum Group Limited stock is -20.18%, while year-to-date (YTD) performance is 6.88%. APM stock has a five-year performance of %. Its 52-week range is between 1.16 and 14.23, which gives APM stock a 52-week price range ratio of 11.32%

Aptorum Group Limited currently has a PE ratio of -6.10, a price-to-book (PB) ratio of 5.63, a price-to-sale (PS) ratio of 102.75, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -66.24%, a ROC of -65.68% and a ROE of -71.12%. The company’s profit margin is -%, its EBITDA margin is -3 064.50%, and its revenue ttm is $327.27 Thousand , which makes it $0.03 revenue per share.

Of the last four earnings reports from Aptorum Group Limited, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Aptorum Group Limited’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Aptorum Group Limited is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Aptorum Group Limited stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aptorum Group Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aptorum Group Limited has a Sell technical analysis rating based on Technical Indicators (ADX : 20.39, ATR14 : 0.32, CCI20 : -157.24, Chaikin Money Flow : -0.23, MACD : -0.20, Money Flow Index : 60.64, ROC : -8.33, RSI : 37.62, STOCH (14,3) : 24.00, STOCH RSI : 0.51, UO : 39.02, Williams %R : -76.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aptorum Group Limited in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Aptorum Group Limited

Aptorum Group Ltd is a pharmaceutical company. It is engaged in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. The pipeline of Aptorum is also enriched through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The firm is also seeking therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms.

CEO: Ian Huen

Telephone: +44 2080929299

Address: 17 Hanover Square, London W1S 1BN, , GB

Number of employees: 39

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

46%54%

Bearish Bullish

58%42%

Bearish Bullish

62%38%

News

Stocktwits